radionuclidi

Radionuclide is a chemical element or isotope whose nucleus is unstable and emits ionizing radiation during its decay to a more stable form. The instability arises when the ratio of protons to neutrons in the nucleus is unbalanced, causing it to undergo radioactive decay processes such as alpha, beta, gamma emission or spontaneous fission. The most common forms of radionuclides observed in nature include naturally occurring isotopes such as uranium‑235, uranium‑238, thorium‑232, and radon‑222, as well as many anthropogenic nuclides produced in reactors, particle accelerators or nuclear weapons testing.

Commercial production of radionuclides is carried out in nuclear reactors, where stable atoms capture neutrons and become transuranic or fission products, and in cyclotrons or linear accelerators that bombard target nuclei with protons or other light ions. The facility type determines the half‑life, radiation type and purity of the isotope. For example, technetium‑99m, produced by the decay of molybdenum‑99 in a reactor, has a half‑life of about 6 hours and emits a useful gamma photon for medical imaging, whereas cobalt‑60 from reactors has a longer half‑life of 5.3 years and emits high‑energy gamma rays for industrial radiography and sterilization.

Applications of radionuclides are diverse. In medicine, diagnostic imaging and targeted radionuclide therapy rely on isotopes such as iodine‑131, lutetium‑177 and actinium‑225. In industry, gamma sources are used to detect material flaws, measure thickness or sterilize food and medical equipment. Scientific research employs short‑lived tracers to study biochemical pathways, environmental transport, and materials science. Energy production harnesses the heat from prolonged decay of long‑lived fuels such as uranium and thorium.

The health and environmental impact of radionuclides depends on their radiation type, energy, and exposure pathways. Ionizing radiation can damage cells and DNA, leading to acute radiation sickness or increased cancer risk. Regulatory frameworks such as the International Atomic Energy Agency guidelines, local licensing authorities and the cleanup of contaminated sites govern safe handling, transport, storage, and disposal. Detection systems (Geiger–Müller counters, scintillation detectors and gamma cameras) monitor exposure levels and ensure compliance with dose limits set by agencies like the ICRP.

Future trends focus on producing cleaner, longer‑lived, and more targeted isotopes for medical and industrial use, while improving waste management and recycling of spent nuclear fuel. Advances in accelerator technology promise on‑site production of short‑lived isotopes, reducing dependence on large research reactors and enabling broader access to critical tracers in medicine and industry.